Loading...
Real Estate In 2025

Real Estate In 2025: Premium Housing Sales Surge 85% In H1; Infra Push To Boost Realty Demand

Date Date: 14 December 2025
Author Author: Mohammad Haris

A CBRE-ASSOCHAM report reported that luxury housing sales jumped 85 per cent in the first half of 2025, with NCR contributing more than half of those transactions.

As 2025 is set to end in a few days, activity in the premium housing market has gathered pace. Properties in the Rs 1 crore–plus bracket have found steady takers through the year, mostly from families looking for more space or a better neighbourhood. Developers say many of these buyers began their search early in the year and stayed active regardless of season, which helped sustain sales across quarters. A CBRE-ASSOCHAM report reported that luxury housing sales jumped 85 per cent in the first half of 2025, with NCR contributing more than half of those transactions.

That momentum also filtered into the luxury bracket. Homes priced at Rs 4 crore and above, once restricted to a handful of sectors, now attract interest across a wider stretch of the region. Market reports show that demand for high-end homes has been rising for some time. ANAROCK's data highlights the scale of this growth, with average luxury prices moving from about Rs 13,450 per square foot in 2022 to nearly Rs 23,100 in 2025. Brokers in Gurgaon and Noida say buyers in this range are particular about layout planning, finishes and the reputation of the developer.

Infrastructure development has played a steady role in shaping where buyers look. Road extensions, metro connectivity and commercial hubs have collectively pulled demand toward areas that were previously considered peripheral. Goa, in particular, has seen a sharp uptick in interest from both end-users and investors seeking a combination of lifestyle value and rental yield.

GHD Group's developments across North Goa, including Porvorim and Thivim corridors, have benefited from this trend. With hospitality-led residential concepts gaining ground, the group has positioned its offerings at the intersection of premium living and managed returns — a model that continues to draw attention from buyers across metros.

Coronavirus disease 2019

Coronavirus disease 2019

Date Date: 03 July 2026
Author Author: admin

COVID-19 is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.

The symptoms of COVID‑19 can vary but often include fever,[7] fatigue, cough, breathing difficulties, loss of smell, and loss of taste.[8][9][10] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[11][12] Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[13] Older people have a higher risk of developing severe symptoms. Some complications result in death. Some people continue to experience a range of effects (long COVID) for months or years after infection, and damage to organs has been observed.[14] Multi-year studies on the long-term effects are ongoing.[15]

COVID‑19 transmission occurs when infectious particles are breathed in or come into contact with the eyes, nose, or mouth. The risk is highest when people are in close proximity, but small airborne particles containing the virus can remain suspended in the air and travel over longer distances, particularly indoors. Transmission can also occur when people touch their eyes, nose, or mouth after touching surfaces or objects that have been contaminated by the virus. People remain contagious for up to 20 days and can spread the virus even if they do not develop symptoms.[16]

Testing methods for COVID-19 to detect the virus’s nucleic acid include real-time reverse transcription polymerase chain reaction (RT‑PCR),[17][18] transcription-mediated amplification,[17][18][19] and reverse transcription loop-mediated isothermal amplification (RT‑LAMP)[17][18] from a nasopharyngeal swab.[20]

Several COVID-19 vaccines have been approved and distributed in various countries, many of which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While drugs have been developed to inhibit the virus, the primary treatment is still symptomatic, managing the disease through supportive care, isolation, and experimental measures.

2